European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I

Autor: Robert Huddart, Johannes Classen, Roberto Salvioni, Rainer Souchon, Walter Albrecht, Xavier Garcia del Muro, Malcolm David Mason, Michael Bamberg, Johnathan Joffe, Jutta Scheiderbauer, Annette Dieing, Oscar Leiva Galvis, Niels E. Skakkebæk, Ronald de Wit, William G. Jones, Sophie D. Fosså, Kai Uwe Koehrmann, H. G. Derigs, Silke Gillessen, Martin Fenner, Sergei Tjulandin, C Clemm, Wolfgang Hoeltl, Padraig Warde, Aude Flechon, Luis Paz Ares, Pieter H.M. De Mulder, S. Kliesch, Nicola Nicolai, Thomas Powles, László Kisbenedek, Lothar Weissbach, Craig R. Nichols, Hans von der Maase, Michael Jewett, Jörg Pont, Markus A. Kuczyk, Volker Loy, Christian Wittekind, Peter Albers, Jose Ramon Germa-Lluch, Felix Sedlmayer, Giovanni Rosti, D. Ondruš, Pilar Laguna, Heinz Schmidberger, István Bodrogi, Gabriella Cohn-Cedermark, Eva Cavallin-Ståhl, Jörg Beyer, Tim Oliver, Arthur Gerl, Gedske Daugaard, Stefan Weinknecht, Tobias Pottek, Hans-Joachim Schmoll, Maike de Wit, Rolf Mueller, Maria De Santis, Michael Hartmann, Graham M. Mead, Oliver Rick, Jean Pierre Droz, Christian K. Kollmannsberger, Hans U. Schmelz, Karim Fizazi, Gosse O N Oosterhof, Lori Wood, Thomas Gauler, Aslam Sohaib, Susanne Krege, Ferran Algaba, Alan Horwich, Eva Winter, Stéphane Culine, Giorgio Pizzocaro, Olbjørn Klepp, Axel Heidenreich, Klaus Peter Dieckmann, Jörg T. Hartmann, Mark Schrader, Lajos Géczi, Carsten Bokemeyer

Publikováno v: European Urology
European Urology, Elsevier, 2008, 53 (3), pp.497-513. ⟨10.1016/j.eururo.2007.12.025⟩
European Urology, 53, 3, pp. 497-513
European Urology, 53, 478-496
European Urology, 53, 3, pp. 478-496
European Urology, 2008, 53 (3), pp.497-513. ⟨10.1016/j.eururo.2007.12.025⟩
European Urology, 53, 497-513
European Urology, 53(3), 478-496. Elsevier
European Urology, 53(3), 497-513. Elsevier

Objectives: The first consensus report presented by the European Germ Cell Cancer Consensus Group (EGCCCG) in the year 2004 has found widespread approval by many colleagues throughout the world. In November 2006, the group met a second time under the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd9ed8b8c70111d50b5d60e842a480f8
https://hdl.handle.net/2066/70330

Current Status of Targeted Therapy in Metastatic Renal Cell Carcinoma

Autor: Cezary Szczylik, Jean-Jaques Patard, Tim Eisen, Thomas Otto, Pieter H.M. De Mulder

Publikováno v: European Urology Supplements. 6:665-671

Over the past few years, considerable advances in the understanding of the pathology and underlying molecular pathways in renal cell carcinoma (RCC) have been translated into the development of targeted therapeutics for this disease. Clear-cell RCC i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::092ffd7aada5d731725a7c39b00a0aad
https://doi.org/10.1016/j.eursup.2007.03.010

Intratumoral Recombinant Human Interleukin-12 Administration in Head and Neck Squamous Cell Carcinoma Patients Modifies Locoregional Lymph Node Architecture and Induces Natural Killer Cell Infiltration in the Primary Tumor

Autor: Gosse J. Adema, Carla M.L. van Herpen, Pieter H.M. De Mulder, Peter C.M. de Wilde, Michiel G.J. Balvers, Jeroen van der Laak, I. Jolanda M. de Vries, Johan H. J. M. van Krieken

Publikováno v: Clinical Cancer Research, 11, 5, pp. 1899-909
Clinical Cancer Research, 11, 1899-909

Contains fulltext : 48590.pdf (Publisher’s version ) (Open Access) The objective of this study was to evaluate the histologic and immunohistopathologic effects of intratumorally given recombinant human interleukin-12 on the immune cells in the prim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::357873d840e5051e61b17812e873ec87
https://doi.org/10.1158/1078-0432.ccr-04-1524

Interferon-α-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma

Autor: Martin Fey, Sophie D. Fosså, Linda de Prijck, Allan T. van Oosterom, Hendrik Van Poppel, Simon Horenblas, J. J. Croles, Pieter H.M. De Mulder, Martine Van Glabbeke, Gerald H. Mickisch

Publikováno v: Cancer. 101:533-540

BACKGROUND In patients with metastatic renal cell carcinoma (MRCC), interferon-α (IFN) monotherapy leads to response rates of 5–15%, dependent on the selection of patients. In 1995, preclinical and clinical data indicated an improvement of these r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c2f7c763e2ca2c2ec4f88057c1aef2c3
https://doi.org/10.1002/cncr.20307

Quality of Life in Good Prognosis Patients With Metastatic Germ Cell Cancer: A Prospective Study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20)

Autor: Sophie D. Fosså, Peter M. Wilkinson, Neil K. Aaronson, Pat Cook, Graham M. Mead, J. Trevor Roberts, Ronald de Wit, Pieter H.M. de Mulder, Sally Stenning, Andrew Bottomley, Laurence Collette, Linda de Prijck

Publikováno v: Journal of Clinical Oncology, 21, 6, pp. 1107-18
Journal of Clinical Oncology, 21, 1107-18

Purpose: To describe global quality of life (GLQL) in patients with metastatic testicular cancer (TC) treated with four different schedules of bleomycin, etoposide, and cisplatin (BEP) chemotherapy (four v three cycles given over 5 v 3 days). Patient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2416f82e7f7832db665c50275e732e7a
https://doi.org/10.1200/jco.2003.02.075